Stellarex 0.035 OTW Drug-Coated Angioplasty Balloon
The Spectranetics Corp. · Decision date Mar 19, 2026
What did the FDA decide?
FDA records P160049/S028 as a supplement to PMA P160049, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 19, 2026.
FDA approval order statement
to incorporate a change to the nylon balloon supplier site for the Stellarex 0.035 OTW Drug-coated Angioplasty Balloon and to reduce the test frequency for the Balloon Burst Test of the Stellarex 035 PTA catheter assembly
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Mar 19, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P160049/S028
- Regulatory pathway
- PMA supplement
- Applicant
- The Spectranetics Corp.
- Product code
- ONU
- Decision code
- OK30
- Decision date
- Mar 19, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Drug-Eluting Peripheral Transluminal Angioplasty Catheter.
- Applicant
- The Spectranetics Corp.
- Product code
- ONU
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P160049/S027 · Related supplement
Stellarex 0.035 OTW Drug-Coated Angioplasty Balloon
P160049/S028 received
Application receipt date recorded by FDA.
P160049/S028 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P160049. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160049
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| The Spectranetics Corp. | PMA supplement | Nov 24, 2025 | FDA |
Explore the linked device profile
Other records with product code ONU
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA supplement | Sep 24, 2026 | FDA | |
Ranger Paclitaxel-Coated Balloon CatheterP190019/S043 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Aug 4, 2026 | FDA |
Lutonix 035 Drug Coated Balloon CatheterP130024/S045 | Lutonix | PMA supplement | Jul 9, 2026 | FDA |
| Medtronic, Inc. | PMA supplement | May 28, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | May 21, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
The Spectranetics Corp.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6531 Dumbarton Cir., Fremont, CA, 94555
Sources and methodology
- Original FDA record: P160049/S028
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
